Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Undecaprenyl phosphate, also known as bactoprenyl phosphate, is an essential C55 isoprenoid lipid that functions as a membrane-bound carrier in bacteria (Source: PubMed, PMID: 16299104). Its primary role is to transport hydrophilic precursors of the cell wall, such as peptidoglycan subunits (Lipid II), across the cytoplasmic membrane to the site of assembly (Source: Nature, doi:10.1038/nature14098). This lipid carrier is recycled through a cycle of phosphorylation and dephosphorylation; specifically, undecaprenyl pyrophosphate must be converted back to undecaprenyl phosphate to initiate a new round of transport (Source: JBC, doi:10.1074/jbc.M110.155010). This recycling process is the target of the antibiotic bacitracin, which forms a complex with the pyrophosphate form in the presence of divalent cations, thereby halting cell wall synthesis and leading to bacterial cell death (Source: StatPearls, NBK536977). Because the undecaprenyl phosphate cycle is unique to prokaryotes and vital for maintaining structural integrity, it is a highly validated target for the development of narrow and broad-spectrum antibacterial agents. Newer antibiotics like teixobactin also interact with this pathway by binding to the lipid-linked precursors, effectively sequestering the carrier and preventing its reuse (Source: Nature, doi:10.1038/nature14098). The essentiality of this carrier across diverse bacterial species makes it a resilient target against the development of resistance, as seen with the slow emergence of resistance to drugs like teixobactin.
Inhibition of lipid carrier recycling by binding to undecaprenyl pyrophosphate and preventing dephosphorylation (e.g., Bacitracin), or by sequestering the lipid carrier to prevent precursor loading (e.g., Friulimicin B).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Undecaprenyl phosphate (C55-P).